UK-based medical imaging firm Brainomix has secured investment to support the advancement of its artificial intelligence (AI)-based software, e-ASPECTS, designed to diagnose and treat stroke.
The $9.8m funding round was led by Parkwalk Advisors and involved Boehringer Ingelheim Venture Fund (BIVF), Chimera Partners and Oxford University Innovation Fund.
Brainomix intends to use the funds to bolster the commercialisation of its medical imaging and workflow software solutions.
Brainomix CEO Dr Michalis Papadakis said: “We welcome BIVF to our team of investors. Their tremendous expertise and heritage in stroke will complement the knowledge of our existing investors.
“Since we started as a spin-out of the University of Oxford we have become a global market leader, with our stroke decision support and workflow tools installed in many leading stroke centres in more than 16 countries.
“With this investment, we will grow around the world and continuously expand Brainomix’s intelligent imaging software for acute stroke care and clinical trials.”
e-ASPECTS automatically implements the Alberta Stroke Program Early CT Score (ASPECTS) method and delivers a quick and standardised assessment of CT scans required to diagnose ischemic stroke.
This capability of the clinical support tool facilitates fast yet consistent treatment decisions that have to be made within few hours of stroke onset, and is expected to enhance patient outcomes while reducing expenses.
BIVF managing director Dr Frank Kalkbrenner said: “Brainomix is a cutting-edge technology company with superior expertise in innovative stroke care.
“Their e-ASPECTS solution significantly supports physicians in the demanding acute care setting and is a step forward for fast and consistent stroke diagnosis.”